NOVAVAX INC
NVAXNasdaq
$8.21
↓ -0.4%Jul 17 close · end-of-day
Price
1Y↑ +18.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.3B
Enterprise Value
$841.2M
P/E
—
P/S
2.2
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$596.3M
Net Income (TTM)
-$87.8M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-13.1%
Net Margin
-14.7%
ROE
60.7%
ROIC
—
Debt / Equity
-2.0
Net Cash
$499.3M
Return 1Y
+17.3%
Company profile
Novavax, Inc. focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial. NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate, is in Phase 3 clinical trial. ResVax is a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
- CEO
- Stanley C. Erck
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 1,990
- Headquarters
- Maryland
- Website
- novavax.com
Management & directors
- Kelly James PatrickEVP, CFO and Treasurer
- Casey Mark JEVP, Chief Legal Officer
- Draghia-Akli RuxandraEVP, Research & Development
- Jacobs John CPresident and CEO
- O'Hara ElaineEVP, Chief Strategy Officer
Roles derived from SEC Form 4 filings.
Earnings
NVAX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$139.5M↓ -79.1%
Diluted EPS-$0.06↓ -102.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $475.6M | $1.1B | $2.0B | $983.7M | $682.2M | $1.1B |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$416.7M | -$1.7B | -$644.7M | -$566.5M | -$248.9M | $452.8M |
| Net income | -$418.3M | -$1.7B | -$657.9M | -$545.1M | -$187.5M | $440.3M |
| Diluted EPS | -$7.27 | -$23.44 | -$8.42 | -$5.41 | -$1.23 | $2.58 |
| Operating cash flow | -$42.5M | $322.9M | -$415.9M | -$714.0M | -$87.3M | -$244.6M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -87.6% | -147.1% | -32.5% | -57.6% | -36.5% | 40.3% |
| Net margin | -87.9% | -152.1% | -33.2% | -55.4% | -27.5% | 39.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $415.5M | $84.5M | $88.3M | $666.7M | $239.2M | $70.4M | $147.1M | $139.5M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $161.0M | -$134.0M | -$131.1M | $515.5M | $101.1M | -$178.0M | $14.2M | -$15.4M |
| Net income | $162.4M | -$121.3M | -$81.0M | $518.6M | $106.5M | -$202.4M | $17.5M | -$9.5M |
| Diluted EPS | $0.99 | -$0.76 | -$0.41 | $2.93 | $0.62 | -$1.25 | $0.28 | -$0.06 |
| Operating cash flow | $314.3M | -$144.8M | -$173.2M | -$185.5M | -$127.5M | $107.8M | -$39.5M | -$32.4M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 38.7% | -158.6% | -148.4% | 77.3% | 42.2% | -252.7% | 9.7% | -11.1% |
| Net margin | 39.1% | -143.5% | -91.8% | 77.8% | 44.5% | -287.3% | 11.9% | -6.8% |
Company news
Jul 14, 2026
Jul 10, 2026
- 10d agoFBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Datafinance.yahoo.com
- 10d agoNovavax (NVAX) Leaves Russell Growth Indexes, Is The 32% Undervaluation Case Convincing?finance.yahoo.com
- 10d agoNovavax (NVAX) Dropped From Major Russell Growth Indices And Why It Mattersfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-20 | Rodgers Richard J | Option exercise | 18,880 | — | — | filing |
| 2026-06-20 | King Rachel K. | Option exercise | 18,880 | — | — | filing |
| 2026-06-20 | DOUGLAS RICHARD | Option exercise | 18,880 | — | — | filing |
| 2026-06-20 | MCGLYNN MARGARET G | Option exercise | 18,880 | — | — | filing |
| 2026-06-20 | MOTT DAVID M | Option exercise | 18,880 | — | — | filing |
| 2026-06-20 | Alton Gregg H | Option exercise | 18,880 | — | — | filing |
| 2026-04-25 | Newton Charles W. | Option exercise | 9,520 | $0.00 | $0.00 | filing |
| 2026-03-10 | Shiver John W. | Option exercise | 7,947 | $0.00 | $0.00 | filing |
| 2026-03-07 | Kelly James Patrick· EVP, CFO and Treasurer | Tax withholding | 5,904 | $9.98 | $58,921.92 | filing |
| 2026-03-07 | Kelly James Patrick· EVP, CFO and Treasurer | Option exercise | 12,223 | $0.00 | $0.00 | filing |
| 2026-03-03 | Jacobs John C· President and CEO | Tax withholding | 69,288 | $9.49 | $657,543.12 | filing |
| 2026-03-03 | O'Hara Elaine· EVP, Chief Strategy Officer | Tax withholding | 22,429 | $9.49 | $212,851.21 | filing |
| 2026-03-03 | Kelly James Patrick· EVP, CFO and Treasurer | Tax withholding | 20,850 | $9.49 | $197,866.50 | filing |
| 2026-03-03 | Casey Mark J· EVP, Chief Legal Officer | Tax withholding | 11,378 | $9.49 | $107,977.22 | filing |
| 2026-03-03 | Draghia-Akli Ruxandra· EVP, Research & Development | Tax withholding | 11,313 | $9.49 | $107,360.37 | filing |
| 2026-03-03 | Jacobs John C· President and CEO | Option exercise | 150,167 | $0.00 | $0.00 | filing |
| 2026-03-03 | Draghia-Akli Ruxandra· EVP, Research & Development | Option exercise | 26,667 | $0.00 | $0.00 | filing |
| 2026-03-03 | Casey Mark J· EVP, Chief Legal Officer | Option exercise | 37,500 | $0.00 | $0.00 | filing |
| 2026-03-03 | O'Hara Elaine· EVP, Chief Strategy Officer | Option exercise | 56,334 | $0.00 | $0.00 | filing |
| 2026-03-03 | Kelly James Patrick· EVP, CFO and Treasurer | Option exercise | 43,167 | $0.00 | $0.00 | filing |
| 2026-03-01 | Jacobs John C· President and CEO | Tax withholding | 38,450 | $10.14 | $389,883.00 | filing |
| 2026-03-01 | Kelly James Patrick· EVP, CFO and Treasurer | Tax withholding | 28,366 | $10.14 | $287,631.24 | filing |
| 2026-03-01 | O'Hara Elaine· EVP, Chief Strategy Officer | Tax withholding | 10,969 | $10.14 | $111,225.66 | filing |
| 2026-03-01 | O'Hara Elaine· EVP, Chief Strategy Officer | Tax withholding | 5,375 | $10.14 | $54,502.50 | filing |
| 2026-03-01 | Casey Mark J· EVP, Chief Legal Officer | Tax withholding | 1,214 | $10.14 | $12,309.96 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.